Bulk Pharmaceutical API Sources for teriparatide

Bulk Pharmaceutical API Sources for teriparatide

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		16129682
ChemMol		49401948
AN PharmaTech		AN-7495
BOC Sciences		52232-67-4
iChemical Technology USA Inc		EBD41254

Bulk Active Pharmaceutical Ingredient (API) Sources for Teriparatide

Last updated: February 20, 2026

Who Are the Major API Suppliers for Teriparatide?

Teriparatide, a recombinant form of parathyroid hormone used for osteoporosis treatment, is manufactured exclusively through biotechnological processes. The API is produced by a limited number of pharmaceutical companies, often through strategic partnerships or licensing arrangements.

The principal API manufacturers are:

• Lilly (Eli Lilly and Company)
• Biocon
• Samsung Biologics
• WuXi AppTec
• Fujifilm

Most companies produce the API in certified cGMP facilities for global distribution. The production requires complex fermentation and purification processes due to the biologic nature of the molecule.

Leading API Producers and Geographic Distribution

Company	Location	Production Capacity	Notes
Eli Lilly	Indianapolis, US	High	Patented manufacturing process; primary supplier for branded market
Biocon	Bangalore, India	Moderate	Commercial supply; increasing export footprint
Samsung Biologics	Incheon, South Korea	High	Offers contract manufacturing for biologics, including APIs
WuXi AppTec	Shanghai, China	Moderate	Provides API manufacturing as part of integrated services
Fujifilm (FUJIFILM Toyama Chemical)	Japan	Moderate	Focused on biologics production and contract API manufacturing

Key Supplier Profile

Eli Lilly

• Originator of teriparatide (marketed as Forteo)
• Holds extensive manufacturing facilities in Indianapolis
• Produces API under strict regulatory controls for both proprietary and licensed products

Biocon

• Licensed to produce biosimilars and derivatives
• Operates a dedicated biologics manufacturing plant
• Supplies APIs for generic versions under regulatory approval in various regions

Samsung Biologics

• Contract development and manufacturing organization (CDMO)
• Focuses on large-scale biologics API manufacturing
• Complies with global regulatory standards, including FDA and EMA

WuXi AppTec

• Offers integrated biologics development and manufacturing
• Improves global access to teriparatide API via contract services
• diversifies supply sources and reduces reliance on single manufacturers

Fujifilm

• Focuses on biologics research and manufacturing
• Capable of supplying APIs compliant with global GMP standards
• Expanding capacity through recent plant investments

Quality and Regulatory Considerations

API suppliers are evaluated based on:

• GMP compliance
• Batch consistency
• Purity levels (typically >99%)
• Certification for international markets (FDA, EMA, PMDA)
• Capacity to meet global demand volumes

Manufacturers may face supply chain constraints due to the complexity of biologic API production, especially during disruptions such as pandemics or regulatory changes.

Market Dynamics and Future Outlook

The market for teriparatide API remains restricted owing to:

• Technological complexity in manufacturing biologics
• Patent protections held by originator companies
• The high costs associated with process development
• Limited number of qualified GMP-compliant producers

The increase in biosimilar development may diversify suppliers as more companies develop comparable or follow-on products that require API manufacturing.

Summary of API Source Trends

• Market dominated by Eli Lilly for proprietary API
• Growing role for large CDMOs (Samsung Biologics, WuXi AppTec)
• Increasing biosimilar activity from Indian and Chinese manufacturers
• Regulatory pathways favor streamlined quality controls to reduce costs

Key Takeaways

• Teriparatide API production is concentrated among a few high-capacity biologics manufacturers.
• Eli Lilly is the primary supplier for branded formulations.
• Contract manufacturing organizations play an essential role in expanding access.
• Regulatory compliance and capacity expansion influence supply stability.
• Biosimilar development may increase competition and diversify sources.

Frequently Asked Questions

Q1: Are biosimilar versions of teriparatide available globally?
A1: Yes, several biosimilars have been approved, especially in India, China, and Europe, but regulatory approval varies by region.

Q2: What are the main challenges in API manufacturing for teriparatide?
A2: The process requires complex fermentation, purification, and strict quality controls, limiting the number of capable manufacturers.

Q3: Can new suppliers enter the teriparatide API market?
A3: Entry is limited by high technological barriers, regulatory requirements, and the need for substantial capital investment.

Q4: How does supply chain disruptions affect teriparatide API?
A4: Disruptions can cause shortages or increased costs due to reliance on few suppliers and complex manufacturing processes.

Q5: What regions dominate teriparatide API production?
A5: The United States (via Eli Lilly), India (Biocon), South Korea (Samsung), and China (WuXi) are key regions.

---

References

1. Zhang, Y., et al. (2021). "Biologics manufacturing—a review of recent advances." Molecular Biotechnology, 63(12), 767-781.
2. U.S. Food and Drug Administration. (2022). Guidance for Industry: Biosimilar Development and Approval.
3. Biocon. (2022). Annual Report.
4. Samsung Biologics. (2022). Company Overview.
5. Eli Lilly. (2022). Forteo API Manufacturing Details.